Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AAK1 | Q2M2I8 | 8/20 | 0.47 |
| ▸ | LMNA | P02545 | 5/20 | 0.43 |
| ▸ | RXFP1 | Q9HBX9 | 4/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | SYK | P43405 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24075380 | 0.81 | LMNA (0.48) | AAK1LMNARXFP1SMN1; SMN2L3MBTL1 | |
| SCHEMBL28821312 | 0.79 | RXFP1 (0.43) | LMNARXFP1SMN1; SMN2L3MBTL1POLB | |
| SCHEMBL28821310 | 0.79 | RXFP1 (0.43) | LMNARXFP1SMN1; SMN2L3MBTL1POLB | |
| SCHEMBL24075680 | 0.79 | AAK1 (0.44) | AAK1LMNASMN1; SMN2KDM4EMAPT | |
| SCHEMBL24075363 | 0.78 | AAK1 (0.43) | AAK1SYK | |
| SCHEMBL31028240 | 0.78 | AAK1 (0.43) | AAK1SYK | |
| SCHEMBL31028283 | 0.77 | AAK1 (0.43) | AAK1SMN1; SMN2KDM4ESYKALDH1A1 | |
| SCHEMBL31028291 | 0.77 | AAK1 (0.43) | AAK1SMN1; SMN2KDM4ESYKALDH1A1 | |
| SCHEMBL24075353 | 0.77 | RXFP1 (0.42) | LMNARXFP1SMN1; SMN2L3MBTL1POLB | |
| SCHEMBL24075355 | 0.74 | POLB (0.46) | LMNARXFP1SMN1; SMN2L3MBTL1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12371434-B2 | MLL1 inhibitors and anti-cancer agents | CHINA NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH CO., LTD. (CN) | 2025-07-29 | — | — | US | disclosed |
| EP-4013754-B1 | MLL1 INHIBITORS AND ANTI-CANCER AGENTS | NOVARTIS AG (CH) | 2024-07-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12371434-B2 | MLL1 inhibitors and anti-cancer agents | MLLT1, BMI1, DOT1L | AAK1 1076/4885LMNA 2414/4885RXFP1 3476/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.